Sigilon Therapeutics Names Deya Corzo Chief Medical Officer

Deya Corzo has been appointed chief medical officer of Sigilon Therapeutics. Corzo comes to the Cambridge, MA, drug developer from women’s health company Sojuournix, where she was senior vice president of R&D and chief medical officer. Her experience also includes posts at uniQure (NASDAQ: [[ticker:QURE]]) and Celgene (NASDAQ: [[ticker:CELG]]). Sigilon has developed a way to encapsulate a cell therapy, protecting it from the immune system. Last year, the company raised $23 million to fund tests of its technology in humans.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.